Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Children's Hospital of Philadelphia

Sites in Philadelphia, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
601
Shown on this page
12
Current sort
Recently updated
Campus scope
Children's Hospital of Philadelphia, Philadelphia, PA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Children's Hospital of Philadelphia, Philadelphia, PA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 37–48 of 601 matching trials with a site at Children's Hospital of Philadelphia, Philadelphia, PA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

NCT02176967
Site status not listed — check the official record
View directory record Official record
Conditions
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neuroblastoma
Interventions
Biopsy Procedure, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Clinical Observation, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Magnetic Resonance Imaging, Ultrasound
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 18 Months
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
193
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 147 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 9:06 AM EDT
Recruiting Phase 1 Interventional

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

NCT07199465
Status at this site: Recruiting
View directory record Official record
Conditions
Cytomegalovirus Prophylaxis
Interventions
Letermovir
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
Up to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 9:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy

NCT07227857
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Epileptic Encephalopathy
Interventions
S230815- Starting dose A, S230815- Dose B, S230815- Dose C, S230815- Dose D
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
2 Years to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Orange, California • Boston, Massachusetts • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 9:06 AM EDT
Recruiting Phase 2 Interventional

Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria

NCT03301038
Status at this site: Recruiting
View directory record Official record
Conditions
Idiopathic Infantile Hypercalcaemia - Severe Form, Genetic Disease, Hypercalcemia, Idiopathic, of Infancy, Hypercalciuric Hypercalcemia, Idiopathic Infantile Hypercalcemia - Mild Form, Hypercalciuria
Interventions
Rifampin
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 9:06 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068
Status at this site: Recruiting
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Teplizumab, Placebo
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
1 Year to 25 Years
Enrollment
723 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
34
States / cities
Scottsdale, Arizona • San Diego, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 9:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

NCT07630974
Status at this site: Recruiting
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Ifinatamab Deruxtecan
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Month to 17 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • St. Petersburg, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 9:06 AM EDT
Recruiting Phase 3 Interventional

A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)

NCT07366034
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Fibrosing Interstitial Lung Disease
Interventions
Nerandomilast, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
2 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 9:06 AM EDT
Recruiting Phase 4 Interventional

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy

NCT05861999
Status at this site: Recruiting
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Months to 24 Months
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
Little Rock, Arkansas • Madera, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 9:06 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

NCT06546670
Status at this site: Recruiting
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
ITU512, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 55 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
9
States / cities
Birmingham, Alabama • Miami, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 9:06 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

NCT05444257
Site status not listed — check the official record
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
72
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 9:06 AM EDT
Recruiting Phase 1 Interventional

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

NCT06173518
Status at this site: Recruiting
View directory record Official record
Conditions
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Interventions
AUTO1
Biological
Lead sponsor
Autolus Limited
Industry
Eligibility
0 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 9:06 AM EDT
Recruiting Phase 1 Interventional

Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

NCT06376162
Status at this site: Recruiting
View directory record Official record
Conditions
Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia, Relapsed/Refractory NPM1-m Acute Leukemia
Interventions
Ziftomenib, Cytarabine, Fludarabine
Drug
Lead sponsor
PedAL BCU, LLC
Other
Eligibility
0 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 9:06 AM EDT

About this Children's Hospital of Philadelphia institution page

What this page lists
ClinicalTrials.gov records that list Children's Hospital of Philadelphia in Philadelphia, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.